Literature DB >> 21547539

Orphanin FQ/nociceptin activates nuclear factor kappa B.

Courtney L Donica1, Vanessa I Ramirez, Hibah O Awwad, Nurulain T Zaveri, Lawrence Toll, Kelly M Standifer.   

Abstract

Endogenous neuropeptide orphanin FQ/nociceptin (OFQ/N) and its receptor, nociceptin orphanin FQ peptide receptor (NOPr), play a modulatory role throughout the body including nociceptive sensitivity, motor function, spatial learning, and the immune system. NOPr is an inhibitory G protein coupled receptor (GPCR) that modulates expression and release of inflammatory mediators from immune cells and in the CNS. Inhibitory GPCRs have been shown to activate the immune and central nervous system regulator, nuclear factor kappa B (NFκB), whose family consists of several subunits. When activated, NFκB translocates to the nucleus and can modify transcription. To determine if OFQ/N modulates NFκB activity, SH-SY5Y human neuroblastoma cells were treated with OFQ/N and assessed for changes in nuclear accumulation, DNA binding, and transcriptional activation. For the first time, we show that OFQ/N increases the nuclear accumulation (1.9-2.8-fold) and the DNA binding of NFκB (2.9-fold) by 2 h as determined by immunoblotting and electromobility shift assay, respectively. OFQ/N induction of NFκB binding to DNA is protein kinase C-dependent and NOPr-specific. OFQ/N stimulated binding of both NFκB p50 and p65 subunits to their consensus binding site on DNA. OFQ/N also induces transcriptional activation of an NFκB reporter gene 2.2-fold by 2 h with an EC(50) of 6.3 nM. This activation of NFκB by OFQ/N suggests a likely mechanism for its modulation of the central nervous and immune systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547539      PMCID: PMC3208742          DOI: 10.1007/s11481-011-9279-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  53 in total

Review 1.  Regulation of nuclear factor kappaB activation by G-protein-coupled receptors.

Authors:  R D Ye
Journal:  J Leukoc Biol       Date:  2001-12       Impact factor: 4.962

Review 2.  Neuronal regulation of immune responses in the central nervous system.

Authors:  Li Tian; Heikki Rauvala; Carl G Gahmberg
Journal:  Trends Immunol       Date:  2009-01-12       Impact factor: 16.687

3.  Electrophoretic Mobility Shift Assay (EMSA).

Authors:  M F Smith; S Delbary-Gossart
Journal:  Methods Mol Med       Date:  2001

4.  Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation.

Authors:  J Peluso; C Gavériaux-Ruff; H W Matthes; D Filliol; B L Kieffer
Journal:  Brain Res Bull       Date:  2001-04       Impact factor: 4.077

5.  Nociceptin/orphanin FQ activates protein kinase C, and this effect is mediated through phospholipase C/Ca2+ pathway.

Authors:  L G Lou; L Ma; G Pei
Journal:  Biochem Biophys Res Commun       Date:  1997-11-17       Impact factor: 3.575

Review 6.  Evidence for a cytokine model of cognitive function.

Authors:  J McAfoose; B T Baune
Journal:  Neurosci Biobehav Rev       Date:  2008-10-18       Impact factor: 8.989

7.  Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.

Authors:  Chitra D Mandyam; Deepak R Thakker; Jennifer L Christensen; Kelly M Standifer
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

8.  LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38alpha-mediated pathway.

Authors:  Feng Hao; Mingqi Tan; Daniel D Wu; Xuemin Xu; Mei-Zhen Cui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-31       Impact factor: 4.733

Review 9.  Nuclear factor kappaB signaling in opioid functions and receptor gene expression.

Authors:  Yulong L Chen; Ping-Yee Law; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

10.  PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination.

Authors:  Shitao Li; Lingyan Wang; Martin E Dorf
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

View more
  7 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 2.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

3.  Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

Authors:  Marta Zielińska; Tanila Ben Haddou; Gerta Cami-Kobeci; Maciej Sałaga; Agata Jarmuż; Milena Padysz; Radzisław Kordek; Mariana Spetea; Stephen M Husbands; Jakub Fichna
Journal:  Eur J Pharmacol       Date:  2015-09-25       Impact factor: 4.432

Review 4.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

5.  Epigenetic modulation of chronic anxiety and pain by histone deacetylation.

Authors:  L Tran; J Schulkin; C O Ligon; B Greenwood-Van Meerveld
Journal:  Mol Psychiatry       Date:  2014-10-07       Impact factor: 15.992

6.  NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.

Authors:  Elaine C Gavioli; Pedro R T Romão
Journal:  J Amino Acids       Date:  2011-11-17

7.  ERK and p38 contribute to the regulation of nociceptin and the nociceptin receptor in human peripheral blood leukocytes.

Authors:  Lan Zhang; Frank Stüber; Christoph Lippuner; Marcel Schiff; Ulrike M Stamer
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.